The University of Pavia is one of the world’s oldest academic institutions: it was founded in 1361 and until the 20th century it was the only university in the Milan area and the region of Lombardy. Today 24,000 students, from both Italy and overseas, study at our University.
The University of Pavia covers all subject areas and is composed of 18 Departments offering study
programmes at all levels, from Bachelor’s degrees to Doctorate programmes. Close attention is paid to each student by our academic staff (900 professors and researchers). 87.5% of our graduates find employment within a year of graduation against a national average of 77%. Master’s degrees in the areas of science, engineering, medicine and pharmacology have a 95% post-graduation employment rate.
SilkFusion will be held at the “Laboratory of Study on Megakaryocyte Function”, directed by Prof. Alessandra Balduini, based in the “Laboratory of Biochemistry, Biotechnology and Advanced Diagnosis” of the IRCCS San Matteo Foundation of Pavia, which is part of the Unit of Clinical Biochemistry of the Department of Molecular Medicine of the University of Pavia.
The Department of Molecular Medicine was founded in 2011 with the aim to develop new interdisciplinary research programmes involving multiple Units engaged in basic laboratory research (Biochemistry, Physiology, Immunology/General Pathology) and human medical research (Genetics, Clinical Biochemistry, Pathology, Cardiology, Haematology). Nowadays, the result is a Department in which the clinical research prevails overall but that retains a strong component of basic laboratory research and aims to bridge the gap between the two halves with the aim of furthering the understanding of the molecular basis of disease and developing new diagnosis and therapies for several major diseases
Alessandra Balduini has a broad background in hematology, with specific training and expertise in research of stem cell and megakaryocyte biology, as well as in the clinical aspects of the diseases related to platelets and clotting processes. She created her research group in 2007, focusing her research on understanding how the different components of the bone marrow microenvironment regulate platelet production. This knowledge laid the groundwork for bio-engineering new 3D models made of porous silk that fully recreates the physiology of the human bone marrow niche environment. By leveraging the biocompatibility, non-thrombogenic features, programmable mechanical properties of silk, these systems allowed functional platelet production ex-vivo.
The Balduini Group includes 1 assistant professor, 4 post-doc and 1 PhD student.

The University of Cambridge is one of the world’s oldest universities and leading academic centers, and a self-governed community of scholars. Its reputation for outstanding academic achievement is known world-wide and reflects the intellectual achievement of its students, as well as the world-class original research carried out by the staff of the University and the Colleges.

Many of the University’s customs and unusual terminology can be traced to roots in the early years of the University’s long history, and this booklet looks to the past to find the origins of much that is distinctive in the University of today.

Dr. Ghevaert’s research group is embedded in the Department of Haematology and based at the NHSBT Blood Centre on the development of stem cell research towards cellular therapies and human application on the biomedical campus. Dr. Ghevaert is a Principle Investigator of the Cambridge Stem Cell Institute supported by the MRC Centre for Regenerative Medicine and the Wellcome Trust.

Resultado de imagen de university of cambridge          Resultado de imagen de blood and transplant

INSERM (Institut national de la santé et de la recherche médicale) is the only public research organization in France entirely dedicated to human health. Its objective is to promote the health of all by advancing knowledge about life and disease, treatment innovation, and public health research.

Since its foundation in 1964, INSERM has played a part in many key medical advances. The Institute is distinguished by both the scientific excellence of its staff, and by its ability to provide benchtop to bedside translational research.

INSERM is the leading European academic biomedical research institution, and with nearly 12,000 publications a year; is second in the world only to the National Institutes of Health (NIH).

Hana Raslova, Research Director (DR2 INSERM) since 2015, is on the head of the Team “From hematopoietic stem cell to megakaryocyte” of the Unit INSERM UMR 1170 localized at Gustave Roussy in Villejuif, France, which is the biggest European Centre dedicated to cancer treatment. The goal of the team is to understand the mechanism of decrease in blood platelets in different disorders to permit new therapeutic approaches. The team comprises together 33 members, some of them will directly participate to the proposal.

 

ISENET, thanks to its participation in several EU Stem Cells research projects (e.g. NeuroScreen, NeuroStemCell, NeuroStemCellRepair), has developed extensive know-how in the characterization, quality control and cryopreservation of neuronal iPSC. Presently is the custodian of very valuable Stem Cells lines (properly consented) derived from European Leading Scientists, which have been characterized, quality controlled and distributed by ISENET. Induced Pluripotent Stem Cell (iPSC) biobanks are an invaluable resource for basic and clinical research since they provide a sustainable supply of accessible cell lines that meet high quality and safety standards. iPSCs are particularly useful to understand disease mechanisms, models for drug development and generation of novel clinical therapies. However, regardless of the end use, it is important that every step in the whole process, starting from the origin to the cell line throughout expansion and manipulation, must be performed and rigorously recorded. ISENET participates actively in the major Biobanking International Societies (ISBER, ESBB and BBMRI) and is an active member of the GET Consortium and chair of the Biobanking and Biosecurity Faculty with the objective to establish an AID Biobank in Africa (for Ebola biospecimen). It is also a member of the Qatar Biobanking Committee supporting its Population Biobank.

Pasquale De Blasio, is an international manager with more than 35 years experience in industrial and academic positions. He is the founder and CEO of Integrated Systems Engineering srl; is very active member of the International Society of Biological and Environmental Biorepositories (www.isebr.org) and founder president of European, Middle Eastern and African Society for Biopreservation and Biobanking (ESBB)

http://www.isenet.it/

CELLINK is a 3D Bioprinting company and global leader in Bioinks for bioprinting of human tissue and organs. CELLINK has created one of the world’s first universal Bioinks, today used by many of the world’s most well-reputed research institutions. Additionally, CELLINK offers several ready to use Bioinks, and custom-made Bioinks to suit specific tissues or cells, along with ready to use cell-mixer configurations for the printing of cellularized constructs. CELLINK currently offers three bioprinters; the INKREDIBLE, the INKREDIBLE+ and the BIO X. BIO X is the new go-to bioprinter for life science companies, researchers and innovators who work with bioprinting. Built to meet the needs of today’s bio-scientists, BIO X allows the user to orchestrate the intricate process of building human tissues. BIO X is the most user friendly bioprinter on the market and a complete standalone product.

http://www.cellink.com

KIM helps companies, research centers, investors and public administrations to improve the return on their R&D investments. It is member of The Knowledge Agents Alliance, together with MRI International and Knowledge Investors (KI). KIM is a reference entity in innovation, knowledge transfer and implementation of scientific technological structures worldwide, whose mission is to improve the competitiveness and the technological progress of companies through specialized services, positioning and consolidating a knowledge transfer model at global level. KIM has developed a portfolio of services focused on satisfying the needs of all actors in the innovation system of the regions in which it operates, from science and technology parks, companies and business associations, to universities, research centers, including public institutions and public administrations. The aim of KIM and its network of collaborators is to cover all phases of the value chain of implementation of dynamization models on innovation, internationalization, infrastructures, business growth and technology and knowledge transfer.

http://www.kimglobal.com/